Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 3
1962 2
1964 1
1968 2
1969 1
1971 1
1977 2
1978 2
1979 1
1980 3
1981 1
1982 2
1983 3
1984 6
1985 12
1986 6
1987 6
1988 4
1989 3
1990 1
1991 2
1992 2
1993 2
1994 1
1995 7
1996 5
1997 4
1998 7
1999 10
2000 11
2001 7
2002 11
2003 11
2004 15
2005 17
2006 10
2007 25
2008 27
2009 18
2010 14
2011 10
2012 23
2013 19
2014 23
2015 24
2016 22
2017 32
2018 32
2019 28
2020 20
2021 24
2022 29
2023 23
2024 27
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

526 results

Results by year

Filters applied: . Clear all
Page 1
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
Sarnaik AA, Hamid O, Khushalani NI, Lewis KD, Medina T, Kluger HM, Thomas SS, Domingo-Musibay E, Pavlick AC, Whitman ED, Martin-Algarra S, Corrie P, Curti BD, Oláh J, Lutzky J, Weber JS, Larkin JMG, Shi W, Takamura T, Jagasia M, Qin H, Wu X, Chartier C, Graf Finckenstein F, Fardis M, Kirkwood JM, Chesney JA. Sarnaik AA, et al. Among authors: takamura t. J Clin Oncol. 2021 Aug 20;39(24):2656-2666. doi: 10.1200/JCO.21.00612. Epub 2021 May 12. J Clin Oncol. 2021. PMID: 33979178 Free PMC article.
Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial.
Takeshita Y, Honda M, Harada K, Kita Y, Takata N, Tsujiguchi H, Tanaka T, Goto H, Nakano Y, Iida N, Arai K, Yamashita T, Mizukoshi E, Nakamura H, Kaneko S, Takamura T. Takeshita Y, et al. Among authors: takamura t. Diabetes Care. 2022 Sep 1;45(9):2064-2075. doi: 10.2337/dc21-2049. Diabetes Care. 2022. PMID: 35894933 Free PMC article. Clinical Trial.
High-carb or low-carb, that is a question.
Igawa H, Takamura T. Igawa H, et al. Among authors: takamura t. Diabetol Int. 2016 Nov 11;8(1):1-3. doi: 10.1007/s13340-016-0296-5. eCollection 2017 Mar. Diabetol Int. 2016. PMID: 30603299 Free PMC article. No abstract available.
Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K, Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group. Ueki K, et al. Lancet Diabetes Endocrinol. 2017 Dec;5(12):951-964. doi: 10.1016/S2213-8587(17)30327-3. Epub 2017 Oct 24. Lancet Diabetes Endocrinol. 2017. PMID: 29079252 Clinical Trial.
Diabetes Accelerates Steatohepatitis in Mice: Liver Pathology and Single-Cell Gene Expression Signatures.
Abuduyimiti T, Goto H, Kimura K, Oshima Y, Tanida R, Kamoshita K, Leerach N, Abuduwaili H, Oo HK, Li Q, Galicia-Medina CM, Takayama H, Ishii KA, Nakano Y, Takeshita Y, Iba T, Naito H, Honda M, Harada K, Yamamoto Y, Takamura T. Abuduyimiti T, et al. Among authors: takamura t. Am J Pathol. 2024 May;194(5):693-707. doi: 10.1016/j.ajpath.2024.01.007. Epub 2024 Feb 1. Am J Pathol. 2024. PMID: 38309428 Free article.
Potential utility of l-carnitine for preventing liver tumors derived from metabolic dysfunction-associated steatohepatitis.
Lyu J, Okada H, Sunagozaka H, Kawaguchi K, Shimakami T, Nio K, Murai K, Shirasaki T, Yoshida M, Arai K, Yamashita T, Tanaka T, Harada K, Takamura T, Kaneko S, Yamashita T, Honda M. Lyu J, et al. Among authors: takamura t. Hepatol Commun. 2024 Apr 12;8(5):e0425. doi: 10.1097/HC9.0000000000000425. eCollection 2024 May 1. Hepatol Commun. 2024. PMID: 38619434 Free PMC article.
Blood pressure reduction with empagliflozin in Japanese patients with type 2 diabetes and cardiovascular diseases: a post-hoc sub-analysis of the placebo-controlled randomized EMBLEM trial.
Tanaka A, Shimabukuro M, Teragawa H, Yoshida H, Okada Y, Takamura T, Taguchi I, Toyoda S, Tomiyama H, Ueda S, Higashi Y, Node K; EMBLEM Investigators. Tanaka A, et al. Among authors: takamura t. Hypertens Res. 2024 Sep;47(9):2295-2302. doi: 10.1038/s41440-024-01725-4. Epub 2024 May 24. Hypertens Res. 2024. PMID: 38789538 Clinical Trial.
526 results